Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival

医学 背景(考古学) 随机对照试验 放射治疗 肺癌 肿瘤科 重症监护医学 内科学 古生物学 生物
作者
Joe Y. Chang,Vivek Verma
出处
期刊:Journal of The National Comprehensive Cancer Network 卷期号:20 (5): 531-539 被引量:10
标识
DOI:10.6004/jnccn.2021.7117
摘要

Metastatic non-small cell lung cancer (NSCLC) is highly heterogeneous, and there are patients with limited areas of metastases (oligometastases) or progression (oligoprogression) whose natural history and prognosis can be considerably more favorable. As a result, local therapy may offer these patients a chance at clinically meaningful disease control and/or cure. This review begins by describing the current status of the existing prospective data, including evidence of overall survival improvements from multiple randomized trials. Given the nascence of this realm, the review then examines ongoing controversies and unresolved issues regarding local therapy for oligometastatic and oligoprogression. First, the role of local therapy in the setting of targeted therapies and immunotherapy is discussed, because most published randomized trials of local therapy have been performed in the context of chemotherapy, which is no longer the standard of care for most patients with metastatic NSCLC. Refining patient selection for local therapy is then reviewed, including clinical factors (such as control of the primary and regional lymph node sites, the heterogeneous definitions of oligometastases/oligoprogression, and the underrepresentation of brain metastases in existing randomized data) and novel pathologic/molecular biomarkers. Next, because there also remains no consensus regarding the optimal modality of local therapy, the advantages and disadvantages of stereotactic radiotherapy, surgery, and other ablative techniques are discussed. Subsequently, methods to optimize radiotherapy are examined, including controversies regarding the optimal dose/fractionation and timing/sequencing scheme. A discussion regarding potentially extending the existing data to polymetastatic NSCLC follows. The review concludes with remarks regarding prudently designing randomized trials of local therapy going forward, including the benefits and drawbacks of specific endpoints meriting further testing in this unique population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鲜于白玉完成签到 ,获得积分10
3秒前
文静季节完成签到,获得积分10
4秒前
Tianling完成签到,获得积分10
6秒前
kokodayour完成签到,获得积分10
12秒前
reflux应助科研通管家采纳,获得10
17秒前
所所应助科研通管家采纳,获得20
17秒前
小胖子完成签到 ,获得积分10
17秒前
22秒前
高贵路灯发布了新的文献求助10
27秒前
卷网那个完成签到 ,获得积分10
29秒前
34秒前
lianxueqi214发布了新的文献求助10
34秒前
华子黄完成签到,获得积分10
39秒前
阳光的幻雪完成签到 ,获得积分10
43秒前
蕉鲁诺蕉巴纳完成签到,获得积分10
43秒前
lienafeihu完成签到 ,获得积分10
46秒前
妮妮完成签到 ,获得积分10
46秒前
摆哥完成签到,获得积分10
47秒前
yangy115完成签到,获得积分10
51秒前
璇璇完成签到 ,获得积分10
51秒前
Jason完成签到 ,获得积分10
55秒前
今后应助爱听歌的青筠采纳,获得10
1分钟前
HaoHao04完成签到 ,获得积分10
1分钟前
luckweb完成签到,获得积分0
1分钟前
xixialison发布了新的文献求助10
1分钟前
1分钟前
OAHCIL完成签到 ,获得积分10
1分钟前
1分钟前
文心同学完成签到,获得积分10
1分钟前
体贴的小翠完成签到,获得积分10
1分钟前
王奥飞完成签到 ,获得积分10
1分钟前
小蕾完成签到 ,获得积分10
1分钟前
轻松思枫完成签到 ,获得积分10
1分钟前
沉默的小耳朵完成签到 ,获得积分10
1分钟前
陈俊雷完成签到 ,获得积分10
1分钟前
先锋老刘001完成签到,获得积分10
1分钟前
比平时多吃点饭完成签到 ,获得积分10
1分钟前
不可靠月亮完成签到,获得积分10
1分钟前
刺猬完成签到,获得积分10
1分钟前
无花果应助ym采纳,获得10
1分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546182
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600285
捐赠科研通 1896399
什么是DOI,文献DOI怎么找? 946273
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557